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ABSTRACT 
Few consistently helpful psychopharmacological interventions have 
been described in the treatment of multiple personality disorder. We 
report a successful open trial of clonazepam for posttraumatic stress 
symptoms in a group of patients with multiple personality disorder. 
Patients reported notable, sustained improvement in sleep, night-
mares, flashbacks, panic attacks and other posttraumatic stress 
disorder symptoms while undergoing clonazepam treatment. The 
authors discuss the limitations of the current study and suggest a 
phenomenological framework for pharmacological interventions in 
multiple personality disorder. 
Patients with multiple personality disorder (MPD) fre-
quently also meet diagnostic criteria for posttraumatic stress 
disorder (PTSD) and patients with PTSD are often de-
scribed as having dissociative symptoms (American Psychiat-
ric Association, 1987; Braun, 1986; Kluft, 1985,1988; Spiegel., 
1984; van der Kolk , 1987). In multiple personality disorder, 
it is thought that dissociative defenses are used to protect the · 
child from the full psychological impact of severe trauma-
usually extreme, repetitive child abuse (Braun, 1986; Kluft, 
1984a, 1985a, 1988; Putnam et aI., 1986). Underthe pressure 
of a variety of developmental factors secondary structuring 
and personification by the child of the traumatically in-
duced dissociated states of consciousness leads to develop-
ment of multiple "personalities" (Kluft, 1984a). Once disso-
ciative defenses are in place, they may be used preferentially 
to handle subsequent traumatic experiences as well as to 
cope with a variety of other developmental vicissitudes (Kluft" 
1984a). 
Reports of several clinical series suggest that, in many 
cases, the symptoms of multiple personality disorder can be 
dramatically alleviated by appropriate treatment with inten-
sive, dynamically-oriented psychotherapy, with adjunctive 
hypnotherapy in selected cases (Kluft, 1984b; Braun, 1986; 
Coons,1986). However, there is no known definitive phar-
macotherapy for the "core" symptoms of multiple personal-
ity disorder (Kluft, 1984b). Adjunctive pharmacotherapy for 
affective, anxiety, and posttraumatic symptoms in multiple 
personality disorder has been tried primarily on an ad hoc 
basis (Barkin R., et aI., 1986; Kluft, 1984b). Sporadic success 
has been reported in individual cases with a variety of agents, 
including antidepressants, lithium, carbamazepine, major 
and minor tranquilizers, beta-blockers and others (Barkin 
et aI., 1986). No consistent pharmacological response pat-
tern has been noted in MPD. There are no controlled, 
double-blind studies in the literature on pharmacotherapy 
for MPD (Barkin et aI., 1986). A few MPD patients have been 
studied in double-blind fashion for presumed treatment 
refractory affective disorders in medication trials at the 
NIMH. Trials of lithium, antidepressants, and carbamazep-
ine failed to ameliorate symptoms in MPD patients in these 
trials (Putnam, unpublished data). 
Benzodiazepines frequently have been used in the treat-
ment of MPD in an attempt to alleviate panic, anxiety and 
posttraumatic stress symptoms including poor concentra-
tion, hyperarousal, fragmented sleep with repetitive night-
mares, anxiety and panic attacks triggered by situations 
which evoke traumata, and intrusive flashbacks of traumatic 
experiences. The authors' clinical experience with a large 
number of multiple personality disorder patients is that ben-
zodiazapenes often have minimal impact on symptoms in 
multiple personality disorder, are often used in ever-increas-
ing doses by the patient, and are commonly abused. Fre-
quently, MPD patients have transient, subjective positive 
responses to psychopharmacological agents, only to relapse 
quickly to their baseline highly symptomatic state (Kluft, 
1984). 
This paper describes an open, non-blind, clinical trial of 
clonazepam for post traumatic symptoms in multiple per-
sonality disorder patients. Clonezepam is a long-acting, 
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high-potency, benzodiazepine with oral anticonvulsant ac-
tivity, originally used to treat several types of epilepsy 
(Browne, 1978; Rosenbaum, 1987) . It has been suggested that 
c10nazepam may have an effect on serotonin systems in the 
brain, leading to a functional increase in serotonin at central 
sites in addition to agonist effects on benzodiazepine recep-
tors (Chadwick et aI., 1977; Chouinard G., 1987; Chouinard 
et aI., 1983; Greenblatt et aI., 1987) . A series of recent reports 
have suggested that c10nazepam has a spectrum of activity 
different from that of other benzodiaze-pines with specific 
efficacy in the treatment of acute mania, schizo-affective 
disorder, and panic disorder (Chouinard et aI., 1983; Choui-
nard, 1987; Fontaine, 1985; Pollack et aI., 1986; Victor et aI., 
1984). Carbamazapene, another orally active anticonvul-
sant which has efficacy in epilepsy and bipolar disorders 
(Ballenger & Post, 1980), has also been reported effective in 
an open trial for posttraumatic stress symptoms in combat 
veterans (Lipper et aI., 1986). 
One of us (RJL) has had favorable experiences with 
c10nazepam in the treatment of mania, schizo-affective dis-
order, atypical psychosis, and anxiety disorders. As will be de-
scribed below, c10nazepam was initially prescribed serendipi-
tously to a patient with multiple personality disorder with 
markedly prominent posttraumatic stress symptoms. Mter a 
significant alleviation of symptoms occurred in this patient, 
additional patients with multiple personality disorder were 
treated with c1onazepam. 
METHODS 
We describe open clinical trials of c10nazepam for post 
traumatic symptoms in a consecutive series of multiple per-
sonality disorder patients. Systematic use of c10nazepam was 
started in these patients after notable success in one case 
(Case 1, below). Patients met all three DSM-III and both 
DSM-III-R criteria for multiple personality disorder and 
DSM-III- R criteria for PTSD (American Psychiatric Associa-
tion , 1980, 1987). In addition, all patients had psychogenic 
amnesia. In each of these cases, clinicians had witnessed 
switching to clear-cut alter personalities demonstrating dif-
ferent overt characteristics from one another and reporting 
relatively separate memory subsystems. Clonazepam treat-
ment was administered to the patients in a non-blind fash-
ion, titrating the medication dosage to optimal therapeutic 
effect balanced against development of side effects, typically 
sedation. 
All patients gave informed consent for use of c1onaze-
pam for post traumatic and dissociative symptoms. 
For each patient included in the study, clinicians com-
pleted a 21-item questionnaire retrospectively rating 1) 
changes in post-traumatic symptoms (based on DSM-III-R 
criteria) rated on a 4-point scale; 2) global improvement of 
the "total human being" on medication; 3) global improve-
ment in utilization of psychotherapy on medication; 4) 
medication side effects and the development of tolerance to 
c1onazepam; and 5) differential effects reported by the alters 
to c1onazepam, if any. Demographic data and history of 
prior medication trials were also reported on the question-
naire. The questionnaire was devised for this study and has 
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not been used in any prior investigation. 
CASE REPORTS 
Case 1: Ms. A is a woman in her late thirties who had been 
treated for approximately two years in intensive psychother-
apy and hypnotherapy for multiple personality disorder sec-
ondary to reported severe, repetitive sadistic sexual, physi-
cal, and emotional abuse perpetrated by both parents from 
about age five until late adolescence. She had been in 
treatmen t for years before the diagnosis of multiple person-
ality disorder was made, receiving a variety of other diagno-
ses including major depressive disorder and schizo-affective 
disorder. Over the years, depressive, anxious, and "psy-
chotic" symptoms had not been ameliorated despite gener-
ally adequate trials of imipramine, amitriptyline, trimipram-
ine, nortriptyline, desyrel, doxepin, fluphenazine, alpra-
zolam, diazepam, and triazolam. Many of these medications 
were tried before the diagnosis of multiple personality disor-
der was made, although others were initiated in an attempt 
to control depressive and anxiety symptoms which contin-
ued after the correct diagnosis was determined. 
The patient's psychotherapy was focused on intensive 
uncovering of memories of traumatic experiences. As she 
recalled more and more traumatic memories, she suffered 
increasingly from crippling posttraumatic panic attacks, 
hyperarousal , intrusive flashbacks, and nightmares com-
pletely disrupting normal sleep. Hypnotherapeutic meth-
ods were not helpful in relieving these symptoms or the 
patient's intense dysphoria. 
Due to multiple somatic complaints, the patient had had 
a very complicated medical history leading to chronic abuse 
of narcotic analgesics, barbiturates, and minor tranquilizers 
necessitating that her husband control access to all medica-
tions . This patien t was effectively disabled much of the time 
due to somatoform, MPD, and PTSD symptoms. 
At that time of the initial consultation, the patient was 
taking imipramine 125 mg per day (with an adequate blood 
level) , alprazolam 0.25 mg t.i .d. and q.h.s., and triazolam 
0.25 mg q.h.s. Dosages of minor tranquilizers were stable at 
this time since the patient's husband controlled access to the 
medication. The patient reported feeling "better" on these 
medications, but outside observers detected little objective 
change or decrease in reports of symptoms on the medica-
tions. 
Initially, through the consultation, attempts were made 
to slow down the pace of uncovering oftraumatic memories, 
increase cooperation among the alters, stabilize the thera-
peutic alliance, and to help the therapist work more directly 
with dependency conflicts and masochistic character prob-
lems presented by the patient. At first, no attempt was made 
to change the patient's medications since the patient pro-
fessed to be reasonably satisfied with her regimen. However, 
as time went on, the patient began to ask if there were a 
medication which might help her more with her chronic 
sleep disorder. Clonazepam was selected because it was a 
long-acting benzodiazapene with known sedating proper-
ties. It was hoped that there might be an additional anti-
anxiety effect, but the consultant did not anticipate any 
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other major change in symptoms with the drug. 
Mter clonazepam 0.5 mg b.i.d. and q.h.s. was substituted 
for the other benzodiazepenes, the patient immediately 
began to be able to sleep five to six hours a night with marked 
decrease in nightmares. With gradual titration upwards the 
patient was eventually stabilized on clonazepam 1 mg b.i.d. 
and 3 mg q.h.s. Ifthe patient awakened in the early morning, 
she took an extra 1 mg of clonazepam and generally was able 
to return to sleep even if a nightmare had occurred. The 
patient stated that for the first time in years she was able to 
return to sleep after awakening. She described significant 
improvement in anxiety symptoms and intensity of flash-
backs. She reported being able to modulate her reaction to 
triggering stimuli which she had previously found over-
whelming. On clonazepam, she felt able to "bounce back" 
from flashbacks allowing her to function more effectively in 
daily living tasks. 
Mter initiation of clonazepam the patient was also able to 
do significant work in psychotherapy for the first time in 
months, working more directly on the issues of identifying 
additional alters and attempting to decrease the level of 
internal warfare among them. 
She has remained on the same dose of clonazepam for 21 
months without development of apparent tolerance or abuse 
of clonazepam. Despite a high level of on-going difficulties 
in many areas, the patient has consistently identified the 
clonazepam as significantly helpful in controlling her sleep 
disturbance, anxiety, flashbacks, and hyperarousal symp-
toms. Her husband and psychotherapist both have con-
curred enthusiastically in this assessment. 
Case 2: Ms. B is a 44 year old divorced female who reported 
an extensive childhood history of neglect and sexual, physi-
cal, and emotional abuse from age two until adolescence. 
She was a highly complex patient with over 180 reported 
alters. She had made major improvements in all aspects of 
her life during five years of intensive out-patient psychother-
apy for multiple personality disorder. However, she could 
only bring traumatic memories into treatment very slowly 
since this was accompanied by frighteningly intense revivifi-
cation experiences which lasted for several days after a 
therapy session. At these times, sleep was markedly disturbed 
by nightmares and she had overwhelming daytime flashback 
experiences and increased dissociative symptoms which 
were disruptive at work and at home. Despite an extensive 
drug abuse history in adolescence and early adulthood, she 
generally resisted medication treatment, only requesting it 
when overwhelmed by posttraumatic nightmares, hyper-
arousal, anxiety and frighteningly intense flashbacks and 
imagery. Prior attempts to ameliorate these symptoms with 
hypnotherapy and modifications in the pace of psychother-
apy did little to change the intensity of these symptoms. 
Intermittent trials of oxazepam, lorazepam and alprazolam 
in varying doses had been ineffective and the patient had 
frequently used more than the prescribed amount of medi-
cation due to severity of symptoms, often rapidly ingesting 
her entire modest prescription without symptom improve-
ment. 
Prior to diagnosis and treatment ofMPD, the patient had 
been treated with little clear-cut results forwhatwere thought 
to be schizo-affective and/or epileptic disorders with ade-
quate trials of neuroleptics, lithium, and carbamazepine. 
Multiple EEGs and extensive neurobehavioral/and neurop-
sychological investigations at that time had all been within 
normal limits. 
Clonazepam 1 mg q.h.s. was started during a harrowing 
period of recalling traumatic memories at a time when the 
patient needed to function at a particularly high level of 
efficacy at work. On clonazepam, there was immediate im-
provemen t in sleep wi th decrease in nigh tmares and dimin u-
tion in intensity of flashbacks and anxiety symptoms during 
the day. Difficulties with work also eased as the patient could 
attend to here-and-now issues without being bombarded by 
flashbacks and bizarre dissociative symptoms. The patient 
found the 1 mg of clonazepam mildly sedating which was 
unusual since she could usually consume excessive dosages 
of other minor tranquilizers almost without noticeable ef-
fect. This patient declined on-going clonazepam treatment. 
She used clonazepam 1 mg q.h.s. p.r.n. successfully for brief 
periods when overwhelmed by posttraumatic stress symp-
toms. No tolerance, abuse, or other side-effects have been 
noted during six months of use of clonazepam. She stated: 
"This stuff really works!" 
Case 3: Ms. C is a woman in her thirties with a reported 
history of extreme physical, emotional, and sexual abuse 
throughout childhood. She had a demandingjob which she 
performed well despite extraordinarily high levels of symp-
toms outside of work. She suffered from overwhelming 
anxiety and panic symptoms, nightmares, and flashbacks 
during which she would mutilate herself and bang her head 
severely. She reported marked disorientation upon awaken-
ing from nightmares, including finding herself running out 
of her house or down the street. She described high levels 
of internal arousal, "like a motor." Trials ofalprazolam and 
lorazepam had failed to alleviate these symptoms. The pa-
tient described taking more and more alprazolam in an 
unsuccessful attempt to dampen her symptoms. 
Her psychotherapy for multiple personality disorder had 
been disrupted due to the unanticipated loss of her thera-
pist. Transition to a new therapist was quite stormy. Despite 
the lack of stability in therapy, which the patient experi-
enced with anxiety and distress, initiation of clonazepam 0.5 
mg q.h.s. led to an immediate improvement in sleep and sig-
nificantdiminution in nightmares, nighttime disorientation 
and fugues. Self-mutilation and head banging were also 
decreased, at least intermittently, apparently due to the 
decrease in panic and anxiety at night. The patient also 
reported improvement in daytime anxiety symptoms with 
p.r.n. doses of clonazepam. Despite this, the patient contin-
ued to report periods of flashbacks, anxiety, panic symp-
toms, and self-mutilation which did not respond to up to 4 
to 5 mg of p.r.n. clonazepam. At this dose, the patient noted 
oversedation and dysfunction in performing her daily tasks. 
This patient was reluctant to take medications on an on-
going basis and resisted seeing the medical consultant for 
medication reasessments. Nonetheless, she found herself 
unable to discontinue clonazepam because she found it "a 
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necessity in keeping things under control". She made efforts 
to not overuse the medication, realizing that at times her 
symptoms would simply exceed the beneficial effects of the 
drug. Mter six months on clonazepam, the patient identi-
fied the medication as consistently helpful in controlling her 
sleep problems and intermittently helpful with other posttrau-
matic symptoms. The therapist described a notable decrease 
in head-banging and self-mutilation episodes. These effects 
persisted even though the patient has remained only tenu-
ously connected to her new therapist. 
Case 4: A 25 year old female had been receiving intensive 
outpatient psychotherapy for multiple personality disorder 
for two years. The patient reported a history of neglect as 
well as emotional, sexual and profound physical abuse per-
petrated by her highly disturbed mother who also met 
criteria for multiple personality disorder based on the pa-
tient's report and several pieces of objective evidence such as 
multiple handwriting styles, wardrobes, bank accounts, etc. 
Incest with the father was suspected but never confirmed. 
The patient's psychiatric treatment history which began 
eight years before the dissociative disorder was suspected 
included a plethora of psychiatric diagnoses, medication 
trials, six psychiatric hospitalizations and a history of epi-
sodic oral substance abuse including alcohol, codeine, ben-
zodiazepenes, and amphetamines. Results of multiple EEGs 
and a CT scan had been within normal limits. Since child-
hood, the patient had complained of symptoms of severe 
anxiety, panic attacks, intrusive thoughts and imagery, 
confusion, "time-loss", and nightmares. In addition, she 
described chronic symptoms of decreased appetite, sadness, 
feelings of worthlessness and hopelessness, suicidal idea-
tion, and sleep disturbances including increased sleep la-
tency, frequent mid-cycle awakening and early morning 
awakening. She experienced recurrent stress-related exac-
erbations of all these symptoms. Symptom worsening char-
acteristically lasted several months, followed by a gradual 
return to baseline. Previous medication trials occurred during 
symptom exacerbations and included adequate unsuccess-
ful trials of five different heterocyclic antidepressants, an 
MAOI, and a brief unsuccessful trial of low dose neurolep-
tics. Trials with diazepam, oxazepam, alprazolam, and te-
mezepam brought variable results. The patient would re-
port initial reduction in anxiety and panic attacks and a 
slight improvement in sleep. The beneficial effects were 
short-lived, however, and the patient began abusing the 
medications with escalating doses in an attempt to control 
symptoms. On one occasion, hospitalization became neces-
sary to withdraw the patient from dangerously high doses of 
alprazolam. 
At the outset of the clonazepam trial, the patient was 
experiencing a particularly severe symptom exacerbation. 
Despite marked storminess in her psychotherapy, she had 
b~en an out-patient and drug-free for over three months. 
Treatment with clonazepam was initiated with a dose of 0.5 
mg q.i.d. and then gradually increased over a week until 
reduction in symptomatology occurred at a dose of 1.0 mg 
q.i.d. The patient reported little if any response to clonaze-
pam before a total dose of 3 mg per day and she was unable 
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to tolerate doses above 4 mg per day because of drowsiness. 
At 4 mg per day, the patient noted an immediate and sub-
stantial decrease in anxiety; the frequericy and severity of 
panic attacks; a dramatic reduction in frequtin~)' of intrusive 
thoughts and imagery; decreased "time-loss;" also less confu-
sion, and improvement in all reported sleep disturbances, 
including nightmares. Her other symptoms of decreased 
appetite, suicidality, and dysphoria remained unchanged, 
however. The patient reported two side-effects: feeling 
emotionally "dulled" and slightly "slowed down" motori-
cally. 
Symptom improvement was steady and enduring over six 
months on 1.0 mg q.i.d. of clonazepam. The patient did not 
increase dosage or abuse this medication during this period. 
In fact, she complained of its inability to get her "high". Mter 
six months, the patient discontinued clonazepam because 
she found new employment requiring a maximal level of 
precise motor coordination. Improved functioning and a 
decrease in symptoms were sustained despite the discontinu-
ation of clonazepam. Recently, however, the patient again 
became acutely symptomatic due to several life stresses. 
Reinstitution of clonazepam 4.0 mg per day induced the 
same improvement as before, permitting more focused work 
in psychotherapy to deal with the life stresses. 
Case 5: Ms. F is a woman in her forties who had been hos-
pitalized on an in-patient psychiatric unit after an acute sui-
cidal crisis. She had been in out-patient treatment for mul-
tiple personality disorder and an apparent major depression 
for about seven years. The patient reported a history of 
sexual, physical, emotional, and confinement abuse at the 
hands of several family members. Abuse had frequently 
occurred at night. The patient stated that she had "always" 
had fragmented and fitful sleep with recurrent nightmares, 
middle and early morning awakening, and total sleep re-
portedly averaging 4 to 5 hours a night. Her depressive 
symptoms had been treated for long periods of time with 
little clear-cut response to trazadone 450 mg daily. Also, she 
had had little response to alprazolam up to 3 to 4 mg a day 
for symptoms of anxiety, panic, hyperarousal, sleeplessness, 
and nightmares. Treatment with clonazepam was initiated 
and the dosage gradually increased to 3 to 4 mg at bedtime. 
At this dose range, the patient reported a disappearance of 
the recurrent nightmares. She denied having a complete 
normalization of sleep on the drug, but she did note less 
sleep fragmentation with longer total sleep time. Clonaze-
pam was also used on an as needed basis for anxiety and 
flashback symptoms during the day. The patient found 0.5 
to 1.0 mg every four to six hours helpful when overwhelmed 
by panic symptoms. No sedation or other side effects were 
described. Total daily dosage rarely exceeded 6 mg per day. 
The patient gradually decreased her nighttime clonazepam 
dosage as her overall symptom status improved during a two 
month hospitalization. On discharge , she was taking 2 mg at 
bedtime and 0.5 mg as needed during the day. This regimen 
has continued for a total of 10 additional months of outpa-
tient treatment. Dosage has remained stable except for 
times of severe crisis when she has transiently used addi-
tional p.r.n . clonazepam during the day and for sleep. 
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GROUP DATA 
The length of clonazepam treatment for this group of 
patients was 6 to 21 months (mean: 11.8 mos.). Standing 
doses of clonazepam ranged from 1.0 mg to 6.0 mg q.d. with 
use of additional p.r.n. doses by several patients at times of 
increased stress. 
Quantification of the data from the PTSD symptom inven-
tory (Table 1) should be regarded very cautiously due to the 
open, non-blind nature of the trial and the lack of validation 
of the symptom questionnaire. Nonetheless, taking the 
median improvement scores on each item, those showing 
the most improvement on clonazepam were, in order: 1) 
nightmares; 2) global improvement of the total human 
being, difficulty falling asleep, intrusive recollections, 
panic/severe anxiety (all equal); and 3) intensity of flash-
backs. (See Table I). 
OTHER CASES 
In addition to these cases, the authors have successfully 
treated a number of additional MPD patients with clonaze-
pam for posttraumatic stress symptoms. Improvement in 
nightmares and insomnia has been the most striking finding 
in these patients, but amelioration of other PTSD symptoms 
such as flashbacks, anxiety, hyperarousal, and panic has 
occurred as well. 
On the other hand, other patients have not had a good 
outcome with clonazepam. Several patients responded to 
clonazepam in a manner more typical of MPD patients 
taking other benzodiazepenes. They reported an initial brief 
decrease in symptoms followed by a rapid recrudesence of 
complaints without response to increases in dosage of medi-
cation. 
DISCUSSION 
Our data suggests that clonazepam may be particularly 
effective in the treatment of refractory posttraumatic stress 
symptoms in some patients with multiple personality disor-
der. Reduction in nightmares and amelioration of dis-
turbed sleep were the most prominent finding in these 
patients. Improvement also occurred in other posttraumatic 
stress symptoms as well as in clinicians' ratings of global im-
provement. Primarily, clonazepam ameliorated the "intru-
sive," "paroxysmal" symptoms of PTSD such as flashbacks, 
nightmares, intrusive imagery, panic attacks, hyperarousal, 
confusion, and irritability. As with other pharmacologic 
interventions in PTSD, clonazepam had relatively little ef-
fecton avoidant symptoms such as numbing, alienation, and 
withdrawal from people (Friedman, 1988, van der Kolk, 
1987). 
One must be cautious in evaluating the results of an open, 
uncontrolled, non-blind clinical trial about which the au-
thors had become enthusiastic after the surprising success in 
case 1. On the other hand, all patients had failed trials of 
other medications and modifications of psychotherapy for 
their symptoms. The same clinicians involved in the clonaze-
pam trials had attempted many of these unsuccessful inter-
ventions. If only placebo factors were at work, one would not 
expect much difference between the effects of clonazepam 
and these other interventions. 
It could be argued that the favorable response in these 
MPD patients is not due to any specific effect of clonazepam. 
Instead, the high binding affinity of clonazepam may permit 
better benzodiazepine receptor saturation accounting for 
the apparent specificity of response to clonazepam (Skolnik, 
personal communication; see also Greenblatt et al. , 1987). 
On the other hand, the authors observed that even very high 
doses of other benzodiazepines had been ineffective in 
several of the same patients who responded to clonazepam. 
Clonazepam is not a curative intervention for PTSD symp-
toms in MPD. In several patients, sufficient additional life 
stress led to symptoms which "broke through" the beneficial 
effect of the medication. On the other hand, any sustained 
symptom reduction was welcomed by most of these patients. 
In addition, successful treatment with clonazepam generally 
allowed more productive psychotherapeutic work to go for-
ward. 
Little abuse of clonazepam was encountered in this group 
of patients, although a number of them had substantially 
misused benzodiazepines and other medications in the past. 
Patien ts were generally maintained on stable doses of clonaze-
pam for months with little pressure to increase the standing 
dose of medication. 
Somewhat surprisingly, patients tolerated relatively high 
doses of clonazepam with few side effects. This may be due 
to the high baseline levels of hyper arousal in MPD patients. 
The latter might also be a factor in most patients' require-
ment for more than a single daily dose regimen of clonaze-
pam, despite the medication's long half-life. Placebo factors 
may be at work here in part, however. 
These data also suggest that clonazepam might be work-
ing in a manner different from that of the other benzodiaz-
epenes in these patients. Carbamazepine, another orally 
active anticonvulsant with beneficial effects on mania and 
schizo-affective disorder, has also been reported efficacious 
in a recent open trial for PTSD symptoms in combat veterans 
(Lipper et al., 1986) . As in the present study, carbamazepine 
was noted to preferentially alleviate the intrusive rather than 
the avoidant symptoms ofPTSD (Lipper et al., 1986). Thus, 
it could be argued that the limbic kindling model suggested 
to explain the effects of carbamazepine in bipolar disorder 
and PTSD may be applicable to the effects of clonazepam on 
PTSD symptoms in MPD (Friedman, 1988; van der Kolk, 
1987). However, in most case reports, carbamazepine has 
not been described as effective in MPD (Barkin et al., 1986; 
KIuft, 1984b; Pu tnam, unpublished data). Further controlled 
studies are warranted on different sub-populations ofPTSD 
and dissociative disorder patients to delineate more pre-
cisely the relative efficacy of carbamazepine and clonaze-
pam in ameliorating PTSD symptoms. Such studies could 
also help clarify the relevance of the limbic kindling model 
of PTSD for theorizing about the neurobiology of MPD. 
In the practical pharmacologic management ofMPD pa-
tients, clonazepam may have advantages over carbamazep-
ine and other agents such as clonidine, propranolol and 
lithium which have been previously described as beneficial 
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in the treatment of PTSD (Friedman, 1988; van der Kolk, 
1987). The use of the latter medications requires a high level 
of consistent patient cooperation. Clonazepam is a relatively 
safe medication, especially for acting out MPD patients who 
are prone to misuse medications or for patients who require 
varying doses of medication because of fluctuations in level 
of symptoms. 
OVERVIEW OF PHARMACOLOGIC APPROACHES 
TOMPD 
Prior discussions of the pharmacological treatment of 
MPD have focused on the importance in medication trials of 
apparent state-dependent medication responses described 
by the different alter personalities (Barkin et aI. , 1986). Al-
though intriguing clinical anecdotes exist about this phe-
nomenon, little rigorous, scientifically acceptable data can 
be found to document it. Until the objective clinical signifi-
cance of this phenomenon is documented in a wide range of 
MPD patients, it seems reasonable to try to target symptoms 
for pharmacological intervention in MPD which cut across 
the whole human being, not those apparently localized in 
separate alter personality states (Kluft, 1984b). 
In devising psychopharacological strategies for MPD, it is 
important to think systematically about the phenomenology 
of the disorder to acquire a list of potential target symptoms. 
Table II heuristically organizes symptoms in MPD into six 
core groups, several of which overlap to some extent. These 
groups are: 1) Process symptoms - including characteris-
tics of alters, interference phenomena between alters (e.g., 
passive influence symptoms) , and switching; 2) amnesia 
symptoms; 3) autohypnotic symptoms; 4) somatoform symp-
toms; 5) PTSD symptoms; and 6) affective symptoms 
(American Psychiatric Association, 1980, 1987; Bernstein 
and Putnam, 1986; Bliss, 1980,1984, 1986; Braun, 1986; Brown 
and Fromm, 1986; Feighner, 1984; Greaves, 1980;·Horowitz, 
1986; Kluft, 1984a; 1985a; 1985b, 1987, 1988; Putnam, 1986; 
., Putnam et aI., 1984; Putnam et aI. , 1986; Spiegel, 1984; 1986; 
Spiegel and Rosenfeld, 1984; van der Kolk, 1986). 
This classification of MPD symptoms was originally de-
vised by the senior author in an attempting to operationalize 
his approach to the differential diagnosis ofMPD and disso-
ciative disorders. Initially he used this framework as an aid 
in teaching, supervision and in clinical research projects 
(Loewenstein et aI., 1986). A somewhat similar typology of 
symptom sub-groups in MPD was independently developed 
by Putnam (unpublished data). Eventually it became clear 
that organizing symptoms in this way could be helpful in 
conceptualizing more systematic approaches to psychophar-
macologic interventions in MPD. 
SYMPTOM CLUSTERS 
Process, amnesia, and autohypnotic symptoms in MPD 
(Groups 1-3) are primarily made up of phenomena which 
can be viewed as either manifestations of intrapsychic de-
fense (attributes and interaction of alters, switching, psycho-
genic amnesia, etc.) and/ or of autohypnotic capacity (spon-
taneous age-regression, self-induced anaesthesia, intense 
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enthrallment experiences, etc.). Of course, from a different 
theoretical vantage point, most of the process and amnesia 
symptoms can also be understood as manifestations of spon-
taneously occurring autohypnotic phenomena (Bliss, 1980, 
1984, 1986; Brown & Fromm, 1986). 
A frequent problem in the management of MPD is the 
attempt to suppressively "treat" dissociation pharmacologi-
cally with the goal of diminishing symptoms such as amnesia, 
switching, and auto-hypnotic phenomena. This approach 
fails to appreciate the adaptiveness of these processes and 
the impossibility, if not the inadvisability, of attempts at their 
permanent suppression at least with our known repertoire 
of psychopharmacologic agents. Since the current litera-
ture on the psychotherapy ofMPD emphasizes that suppres-
sive psychological treatments are usually inefficacious and 
counterproductive (Braun, 1986; Kluft, 1984b, 1985a, 1988), 
it seems unlikely that suppressive psychopharmacological 
approaches would prove to be a useful alternative. 
Additionally, true manifestations of intrapsychic defense 
per se (e.g. , repression, dissociation, reaction formation, 
projection, etc.) and autohypnosis are generally unrespon-
sive to attempts at direct psychopharmacological modifica-
tion at least by currently available drugs. The authors are well 
aware, however, that appropriate pharmacological interven-
tions can improve the overall level of ego-functioning in 
many patients with a wide variety of disorders (Group for the 
Advancement of Psychiatry, 1975). The point of this discus-
sion is to clarify the way that this might occur in MPD 
patients. 
Similarly, in MPD, antipsychotic medications are often 
initiated in an attempt to "treat" the auditory and visual 
hallucinations and passive-influence symptoms. Passive in-
fluence symptoms, hallucinations, and pseudohallucina-
tions (voices, images or sensations experienced within the 
mind, not outside it) in MPD are generally best understood 
as manifestations of the alter personalities and their interac-
tions or of posttraumatic flashbacks and imagery (Putnam et 
aI., 1984). In addition, the MPD patient's posttraumatic mis-
trustfulness and sensitivity are frequently misinterpreted as 
representing a true paranoid process. The patient's tempo.:. 
rary diminution in reality testing during severe flashbacks is 
also interpreted as "psychotic". Thus, symptoms related to 
traumatization and dissociation, reflections of relatively high-
level ego defenses and of autohypnosis, are incorrectly con-
ceptualized as representing a core psychotic process or 
vulnerability (Bliss, 1984; Putnam et aI., 1984). A few MPD 
patients do report beneficial effects from neuroleptics. In 
most cases, however, careful questioning reveals that the 
improvement is primarily due to diminution in anxiety and 
hyperarousal symptoms, and only secondarily to an effect on 
the apparent psychotic symptoms. 
Somatoform symptoms in MPD (Group 4) also are often 
targeted pharmacologically. Somatoform pain symptoms 
and pseudoseizures are most frequently treated in this way 
with analgesics and anticonvulsants, respectively. Use of 
narcotic analgesics for somatoform pain symptoms in MPD 
is almost invariably inefficacious in the long run and fre-
quently leads to abuse of the medications. It is usually 
preferable to approach somatoform symptoms in MPD 
i 
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generally does not meet true criteria for affective disorder I 
since usually only a few alters will report depressive symp- I 
toms while others describe euthymia or even apparent I 
hypomania (Putnam et al., 1984) . Clinicians frequently mis-
take the state of one or more alters for that of the whole 
human being (Loewenstein et al., 1987) . In general, even 
when all alters report a depressive syndrome, this is a tran-
sient phenomenon related to an acute crisis. Thus, the time-
course criteria for major depression by DSM-I1I/ DSM-I1I-R 
criteria is also rarely met in MPD patients (Putnam et al., 
1984). 
psychotherapeutically or hypnotherapeutically as manifes-
tations of somatic memory phenomena or of internal con-
flict among alters. Pseudoseizures are conversion symptoms 
for which no known pharmacologic treatment exists. The 
non-MPD literature on somatoform disorders also generally 
supports non-pharmacological interventions for these con-
ditions, except to treat other intercurrent psychiatric disor-
ders such as affective or anxiety disorders (see for example, 
Ford,1983). 
Only PTSD and affective symptoms (Groups 5-6) appear 
to be valid psychopharmacological targets in MPD. Mfective 
symptoms are often targeted for treatment but the literature 
and clinical experience strongly suggest that antidepres-
sants are rarely efficacious in MPD (Barkin et al., 1986; Kluft, 
1984b; Putnam, unpublished data). There are several expla-
Although an early report hypothesized that MPD was an 
"epiphenoma" of primary affective disorder (Coryell, 1983), 
it is probably more correct to conceptualize depression in 
TABLE I 
PTSD Symptom Improvement with Clonazepam in FIVE Consecutive MPD Cases 
(In rank order of improvement based on median change score)* 
Median 
CASE 1 2 3 4 5 Change 
Score 
Nightmares 3+ 2+ 3+ 2+ 3+ 3+ 
Global Improvement of 
Total Human Being 2+ 2+ 2+ 2+ 1+ 2+ 
Difficulty Falling Asleep 3+ 2+ 2+ 1+ 1+ 2+ 
PaniC/Severe Anxiety 2+ 1+ 2+ 3+ 1+ 2+ 
Intrusive Recollections 2+ 2+ 1+ 2+ 1+ 2+ 
Flashbacks 2+ 2+ 1+ N/A 1+ 1.5+ 
Reactivity to Triggers 1+ 1+ 1+ 2+ 1+ 1+ 
Irritabilityl Anger 1+ 1+ 1+ 2+ N/A 1+ 
Difficulty Concentratingl 
Confusion 1+ 2+ 1+ 3+ 1+ 1+ 
Exaggerated Startle 1+ 1+ 1+ N/A 0 1+ 
Physiologic React to 
Triggers 2+ 1+ 2+ 1+ 1+ 1+ 
Hypervigilance 1+ 0 1+ N/A 0 0.5+ 
Psychogenic Amnesia 0 0 0 2+ 0 0 
Avoidance Symptoms 1+ 0 0 0 1+ 0 
* (Key: No change=O; Mild Improvement=1+; Moderate Improvement=2+; Marked Improvement=3+) 
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r' MPD as a secondary affective disorder; that is, an affective 
disorder co-existing with another primary Axis I DSM-III/ 
DSM-III-R disorder (Goodwin & Guze, 1979). Therefore, 
even without the problem of the apparent state dependency 
of the affective symptoms in MPD, one would predict a more 
heterogeneous, less robust, response to antidepressant 
medication in MPD than in primary affective disorder. In 
addition, many of the apparent vegetative symptoms in 
MPD, such as sleep disturbance, poor concentration, and 
irritability, may be better conceptualized as manifestations 
of PTSD, not of an affective disorder. 
Posttraumtic stress symptoms remain as the most promis-
ing psychopharmacological target in MPD patients. To be 
sure, there are MPD patients who report state dependency of 
certain PTSD symptoms such as panic, irritability, awareness 
or flashbacks, nightmares, etc. On the other hand, in 
clinical practice, at least some PTSD symptoms seem to 
manifest themselves in many if not all alters. Even alters who 
claim invulnerability to dysphoria of any kind will often show 
at least indirect evidence of posttraumatic reactivity. Not all 
MPD patients will meet full criteria for PTSD. Most MPD 
patients will, however, report at least some PTSD symptoms 
such as nightmares, reactivity to triggers or hyperarousal. It 
may be difficult to identify specific posttraumatic triggers in 
MPD, however. In child-abuse related PTSD syndromes, the 
triggers are often mundane objects or situations which 
evoke abuse experiences or locations where abuse actually 
occurred (van der Kolk, 1986). Phobic avoidance of these 
panic-inducing triggers may occur leading to a misdiagnosis 
of agoraphobia with panic attacks. 
CONCLUSIONS 
Our study suggests that clonazepam has potential as an 
adjunctive treatment for the amelioration of PTSD symp-
toms in MPD. Clonazepam is safe, easy to use, and not 
associated with significant problematic side effects or abuse 
in this sample. Our findings need to be replicated in well-
constructed double-blind studies of MPD patients taking 
clonazepam. In addition, longer term efficacy, side-effects, 
and development of tolerance to clonazepam in MPD pa-
tients with PTSD need to be evaluated longitudinally. No 
double-blind trials have yet been published to document the 
utility of any medication treatment in PTSD, although sev-
eral are currently in progress (Friedman, 1988). Clonaze-
pam has been shown to be safe and effective in the treatment 
TABLE II 
Symptom Clusters in MPD 
Process Symptoms 
1. Alter Attributes 
(e.g. different stated age, gender, self-presentation/forms 
of self-expression, memory subsystems, etc.) 
2. Passive Influence SymptomS/Interference Phenomena 
3. Hallucinations/Pseudo-hallucinations 
5. Linguistic usage (e.g. use of 1st person plural, 3rd person 
Singular when referring to self; use of different names for 
self) 
6. Switching Phenomena 
Autohypnotic symptoms 
(manifested by high hypnotizability) 
1. Enthrallment 
2. Spontaneous Age Regression 
3. Negative Hallucinations 
4. Voluntary anaesthesia 
5. Out of body Experiences 
6. Trance Logic 
7. Eye-roll with switching 
Amnesia Symptoms 
1. Blackouts/Time loss 
2. Fugues 
3. Perplexing Possessions 
4. Inexplicable Changes in Relationships 
5. Fluctuations in Skills/Habits/Knowledge 
6. Fragmentary Recall of Entire Life History 
7. Chronic Mistaken Identity Experiences 
8. "Micro"-Dissociations 
10 
Somat%rm Symptoms 
1. Conversion symptoms 
2. Pseudoseizures 
3. Somatization disorder/Briquet's Syndrome 
4. Somatoform Pain Symptoms (e.g. headache, abdominal 
pain) 
5. Somatic memory 
PTSD Symptoms 
1. Psychological Trauma 
2. Flashbacks/Revivifications/Intrusions (Hyperamnesia) 
3. Nightmares 
4. Reactivity to Triggers 
5. HyperarousallStartle Response 
6. Panic/Anxiety 
7. N umbingi A voidance/Detachment 
Affective Symptoms 
1. Depressed mood (differentiate between mood disorder 
localized in specific alter(s) versus across "total human 
being") 
2. Hypomania/Mood swings (differentiate between mood 
disorder localized in specific alter(s) versus across "total 
human being"; mood swings not due to interference phe-
nomena between alters) 
3. Vegetative symptoms (must be differentiated from PTSD 
symptoms; e.g., middle of night awakening due to night-
mares, etc.) 
4. Suicidal thoughts/attempts/self-mutilation 
5. Guilt 
6. Helpless/Hopeless 
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of mania and panic attacks (Rosenbaum, 1987). We feel that 
it is important to study further the efficacy of clonazepam in 
populations with severe, disabling chronic post traumatic 
symptoms such as MPD patients, non-MPD child abuse sur-
vivors, and combat veterans with PTSD. 
In addition, targeting of PTSD symptoms readily lends 
itself to a general strategy for evaluating psychopharmacol-
ogic interventions in MPD. As the neuropharmacology of 
PTSD is clarified in various populations such as combat 
veterans, incest-survivors, MPD patients, and other trauma 
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